home page

News

Archive


Date Press Releases Link to PDF File
June 23, 2011 NeurAxon Announces Presentations at the 2011 BIO International Convention and the World Drug Targets Summit
PDF version
Nov 9, 2010 NeurAxon, Inc. to Present at Lazard Capital Markets 7th Annual Healthcare Conference November 16, 2010
PDF version
Oct 31, 2010 NeurAxon Announces NXN-188 Phase 2 Data Demonstrating Efficacy in Acute Migraine
PDF version
Oct. 26, 2010 NeurAxon's NXN-188 Named One of 10 Most Promising Neuroscience Projects by Windhover
PDF version
Oct. 14, 2010 NeurAxon Named One of Canada’s Top 10™ Life Science Companies
PDF version
Sept. 29, 2010 NeurAxon Announces Closing of Convertible Debenture Financing
PDF version
Sept. 28, 2010 NeurAxon, Inc. to Present at Upcoming Investor and Business Development Conferences
PDF version
July 29, 2010 NeurAxon, Inc. to Present at BMO Capital Markets 10th Annual Focus on Healthcare Conference August 5, 2010
PDF version
June 2, 2010 NeurAxon, Inc. to Present at 9th Annual Needham Healthcare Conference June 9, 2010
PDF version
May 18, 2010 NeurAxon, Inc. to Make Multiple Presentations at the International Symposium on Nitric Oxide and Other Gaseous Neurotransmitters
PDF version
Jan 11, 2010 NeurAxon Awarded Grant from The Michael J. Fox Foundation to Research Novel Treatment Approach for Parkinson’s Disease
PDF version
Dec. 29, 2009 NeurAxon Announces Closing of Convertible Debenture Financing
PDF version
Nov. 12, 2009 NeurAxon, Inc. to Present at Upcoming Investor and Business Development Conferences
PDF version
Oct. 22, 2009 NeurAxon, Inc. to Present at Upcoming Investor and Business Development Conferences
PDF version
Sept. 8, 2009 NeurAxon, Inc. to Present at Upcoming Investor and Medical Conferences
PDF version
Mar. 27, 2009 NeurAxon, Inc. to Present at the BIO National Venture Conference April 1, 2009
PDF version
Nov. 18, 2008 NeurAxon, Inc. to Present at 20th Annual Piper Jaffray Health Care Conference December 2, 2008
PDF version
Oct. 27, 2008 NeurAxon's NXN-188 Named One of 10 Most Promising Neuroscience Projects by Windhover
PDF version
Oct. 23, 2008 NeurAxon, Inc. to Present at the BIO Investor Forum October 30, 2008
PDF version
Oct. 16, 2008 NeurAxon, Inc. to Present at First Annual Boston Biotech R&D Conference October 22, 2008
PDF version
Sept. 16, 2008 NeurAxon Appoints Thomas Lategan, PhD as Vice President of Regulatory Affairs
PDF version
Sept. 5, 2008 NeurAxon’s NXN-188 Demonstrates Pain Relief in Migraine with Aura
PDF version
June 17, 2008 NeurAxon, Inc. to Present at BIO International Convention June 18, 2008
PDF version
Mar. 25, 2008 NeurAxon, Inc. to Present at the BioCentury Future Leaders Conference March 27, 2008
PDF version
Mar. 11, 2008 NeurAxon Announces the Appointment of David Brand
to Its Board of Directors
PDF version
Feb. 7, 2008 NeurAxon, Inc. to Present at 10th Annual BIO CEO & Investor Conference
PDF version
Jan. 4, 2008 NeurAxon, Inc. to Present at 26th Annual JPMorgan Healthcare Conference January 10, 2008
PDF version
Aug. 20, 2007 NeurAxon Announces $32 Million Series B Financing
PDF version
Aug. 14, 2007 NeurAxon Announces Positive Phase 1 Trial Data on NXN-188 for Migraine
PDF version
Aug. 7, 2007 NeurAxon Appoints Robert Medve, MD, as Chief Medical and Regulatory Officer
PDF version
July 31, 2007 NeurAxon Appoints Lawrence E. Bloch, MD, JD, as Chief Executive Officer
PDF version

 

Home | NeurAxon | Market | Pipeline | Research | News | Contact